List view / Grid view

Articles

Discovering the principles of nervous system function

23 November 2023 | By

Dr William Schafer, of the MRC Laboratory of Molecular Biology, focuses on the cellular and molecular mechanisms of behaviour, which is one of the fundamental problems of biology. Schafer and his colleagues have studied the nematode Caenorhabditis elegans, using a variety of approaches such as optogenetic neuroimaging and high content…

Combining autotaxin and TGF-β inhibitors in cancer

22 November 2023 | By

Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…

Natural killer cells: Looking good for cancer therapy

17 November 2023 | By

The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?

Antimicrobial resistance with Recce Pharmaceuticals

16 November 2023 | By

In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of…

Breaking new ground in endometriosis treatment

14 November 2023 | By

Endometriosis is a debilitating condition that affects millions of women worldwide, causing chronic pain, infertility, and a host of other distressing symptoms. Current treatments offer limited relief, but they do not address the cause of the disease. Professor Hugo Vankelecom, at the helm of the CurE-me project, is on a…

Navigating the challenges of cell therapies

8 November 2023 | By

Cell therapies hold great potential for treating complex diseases, yet they face significant limitations and challenges. Current cell therapies have difficulty distinguishing between healthy and cancerous cells, often resulting in adverse effects. Vittoria's innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of…

The power of combinations in blood cancers

6 November 2023 | By , ,

Haematology research is a cradle of innovation, with many firsts in therapeutic approaches utilising the latest technology for the treatment of blood cancers. Anas Younes, Senior Vice President, Head of Haematology Oncology Research and Development at AstraZeneca, envisions a future where potential cures are within reach for more blood cancers…